Glucocorticoid Receptor Modulator - Grunenthal
Latest Information Update: 24 Oct 2024
Price :
$50 *
At a glance
- Originator Grunenthal
- Class Anti-inflammatories
- Mechanism of Action Glucocorticoid receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Inflammation
Most Recent Events
- 22 Oct 2024 Phase-I development in Inflammation (In volunteers) is ongoing in Germany (PO)
- 22 Oct 2024 Grünenthal completes a phase I trial in Inflammation (In volunteers) in Germany (PO) before October 2024
- 28 Aug 2024 No recent reports of development identified for phase-I development in Inflammation(In volunteers) in Germany (PO)